20 May 2019 - 08:55
Serodus ASA has successfully completed a directed share issue of NOK 499.200.
Serodus’ Board of Directors has, based on the issue authorization granted by the annual general meeting on 29 May 2018, issued new shares at a subscription price of NOK 1.30. The Company received NOK 499.200.
The proceeds of the Share Issue will be used for: 1) finalization of the ongoing regulatory required toxicological testing before long-term administration of SER150 in clinical trials, 2) production of clinical material and 3) preparation of the coming clinical trial in diabetic patients with kidney disease.